{'fraction_non_alphanumeric': 0.019169329073482427, 'fraction_numerical': 0.001597444089456869, 'mean_word_length': 6.044943820224719, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ledipasvir/sofosbuvir‐associated photosensitivity in a case with chronic hepatitis C

Direct-acting antiviral agents (DAAs) drastically increase the tolerability to and efficacy of the chronic hepatitis C treatment compared to the historic regimen of pegylated interferon and ribavirin. The most common adverse events associated with DAAs are fatigue and headache, but various abnormal cutaneous effects including photosensitivity have been reported, especially with the use of simeprevir/sofosbuvir.1 Here we present a case developing photosensitivity due to ledipasvir/sofosbuvir during the treatment of chronic hepatitis C.